Fisher & Paykel Healthcare Corporation Limited
FPH.NZ · NZE
Company research
Fisher & Paykel Healthcare Corporation Limited (NZE: FPH) is a leading New Zealand-based global designer, manufacturer, and marketer of medical device products and systems for use in acute and chronic respiratory care, surgery, and the treatment of obstructive sleep apnea (OSA), with its products sold in over 120 countries worldwide. Founded in 1934 and headquartered in Auckland, New Zealand, the company operates across two primary segments — Hospital and Homecare — offering a comprehensive portfolio that includes humidification systems, nasal high flow therapy devices, invasive and noninvasive ventilation solutions, CPAP masks, flow generators, and data management technologies. Recognised as one of the three largest respiratory care device companies globally, Fisher & Paykel Healthcare holds a market-leading position in hospital humidifiers and related consumables, and ranks as the third-largest player in the home-based treatment of sleep apnea. With manufacturing facilities in New Zealand and Mexico, approximately 7,500 employees worldwide, and a market capitalisation of approximately NZ$22.6 billion, the company generates around 42% of its revenue from the United States, 32% from Europe, and 18% from the Asia-Pacific region.
Research reports
A data-driven fundamental and valuation report that profiles FPH’s business, recent share price performance, earnings and revenue trends, margins, leverage, dividend policy, and volatility, while presenting analyst consensus targets and fair value estimates that frame the shares as modestly premium-valued but supported by double-digit forecast earnings growth and generally strong balance sheet and profitability metrics.
Simply Wall St · May 31, 2026Why Fisher & Paykel Healthcare (NZSE:FPH) Is Up 10.8% After Strong FY26 Profit And Higher DividendExamines FPH’s FY26 results and dividend increase as drivers of the recent share price rally, highlighting stronger sales and net income alongside an upgraded dividend, but flags ongoing margin pressure from tariffs, competition and hospital budget constraints plus valuation debate among analysts, resulting in a mixed view that balances near-term earnings catalysts against longer-term profitability risks.
AusNZ Finance Daily · May 28, 2026FPH.NZ Stock Surges on FY26 Results & FY27 OutlookProvides a full-year FY26 review and FY27 guidance analysis, emphasizing 14% revenue growth, 24% NPAT growth, expanding gross and operating margins, strong operating cash flow and low leverage, plus a 22% dividend increase, and argues that structural demand, margin recovery and product adoption justify FPH’s premium valuation while acknowledging risks from tariffs, potential hardware sales moderation and FX volatility.
The Bull · May 25, 2026Fisher & Paykel Shares Lead ASX 200, as Margins Prove ResilientDiscusses FPH’s FY26 result and FY27 guidance in the context of a sharp share price rally, highlighting robust profit growth, strong demand in hospital consumables and OSA masks, management’s detailed plan to offset ~50bps margin headwinds from tariffs and logistics through efficiency gains, and a long-run path toward mid‑60s gross margins, while outlining bull and bear cases around hardware demand normalisation, tariff uncertainty, FX risk, and valuation after the post‑earnings bounce.